Fukuhara, Takasuke

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

Mlcochova, P., Kemp, S. A., Dhar, M. S., Papa, G., Meng, B., Ferreira, I. A. T. M., Datir, R., Collier, D. A., Albecka, A., Singh, S., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 1,337

Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity

Meng, B., Abdullahi, A., Ferreira, I. A. T. M., Goonawardane, N., Saito, A., Kimura, I., Yamasoba, D., Gerber, P. P., Fatihi, S., Rathore, S., et al. (2022) · Nature

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 1,146

SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity

Motozono, C., Toyoda, M., Zahradnik, J., Saito, A., Nasser, H., Tan, T. S., Ngare, I., Kimura, I., Uriu, K., Kosugi, Y., et al. (2021) · Cell Host & Microbe

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 586

Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study

Akahata, W., Sekida, T., Nogimori, T., Ode, H., Tamura, T., Kono, K., Kazami, Y., Washizaki, A., Masuta, Y., Suzuki, R., et al. (2023) · Cell Reports Medicine

SARS-CoV-2 and COVID-19 ResearchRNA Interference and Gene Delivery

Cited by 41

Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine

Aboshi, M., Matsuda, K., Kawakami, D., Kono, K., Kazami, Y., Sekida, T., Komori, M., Morey, A. L., Suga, S., Smith, J. F., et al. (2024) · iScience

SARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testing

Cited by 36